Navigation Links
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry

SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Chen Chen has been appointed Senior Vice President of Chemistry Services.

Prior to joining Sundia, Dr. Chen worked at Neurocrine Biosciences, a drug discovery and development company in San Diego, USA for 15 years, from a staff scientist to Senior Director of Medicinal Chemistry of Neurocrine. In his research and management positions at Neurocrine, Dr. Chen achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (aka NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies. Elagolix, the most advanced in this class, is currently finishing Phase II trials by Neurocrine for the treatment of endometriosis. Dr. Chen designed, synthesized and developed NBI-30775 (R121919), a small molecule antagonist of the corticotrophin-releasing factor receptor as the first-in-class compound advanced into clinical trials for depression/anxiety. Dr. Chen also discovered NBI-31772, the first small molecule inhibitor for the insulin-like growth factor-I/IGF-binding protein. In addition, Dr. Chen identified the first selective antagonist of the melanocortin-5 receptor, and discovered numerous agonists and antagonists for the melanocortin-4 receptor for eating disorders.

Dr. Chen has extensive experience in CNS drug research and GPCRs as drug targets. His knowledge also includes neuropathic pain and metabolic disorders. His research interests extend to clinic and preclinic pharmacokinetics of small molecules and the relationship with their chemical properties.

"It is an honor for Sundia to have world class leading scientists as Dr. Chen in our senior management team. As our clients worldwide are bringing more and more high technical level drug discovery programs to Sundia, Dr. Chen and other scientists at Sundia with excellent track record in drug discovery will make Sundia highly competent to deliver outstanding services to our clients," commented by Dr. Xiaochuan Wang, Chairman and CEO of Sundia.

Dr. Chen received his bachelor's degree in Chemistry from Xiamen University, and his Ph.D. degree from the prestigious Shanghai Institute of Organic Chemistry under the supervision of the late Professor Yao-Zeng Huang, member of the Chinese Academy of Science. He also obtained his postdoctoral training with Professor Sir Derek H. R. Barton, a Nobel Laureate at Texas A&M University in USA. Dr. Chen has so far published near 130 scientific papers in peer-reviewed journals such as J. Am. Chem. Soc., J. Org. Chem., J. Med. Chem., and J. Biol. Chem. He has written numerous review articles on the topics of drug discovery and medicinal chemistry. He is the co-inventor of over 25 US patents. He has been invited to give presentations in numerous scientific conferences such as the Gorden Conference of Medicinal Chemistry and the ACS National Meeting.

About Sundia

Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) company based in Shanghai, China, to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, formulation development, API manufacture, and regulatory submission. For more information, please visit .

SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Finland Biotech Delegation Visits Sundia
2. CRO Company Sundia Welcomes New Members to Its Executive Team
3. Golden Meditech Announces Financial Year 2008/09 Annual Results
4. Doylestown Hospital and Perot Systems Successfully Implement Advanced MEDITECH 6.0 Platform
5. Sentillion Introduces Advanced Authentication Solution For Direct Access to Cerner, Eclipsys, Epic, McKesson and MEDITECH Applications
6. Golden Meditech Releases FY2008/09 Q3 Results
7. Golden Meditech Brings in Financial Investor Through New Share Issuance
8. Golden Meditech Releases FY2008/09 Interim Results
9. Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems
10. Golden Meditech Increases Stakes in Cordlife, Largest Cord Blood Bank Operator in Southeast Asia
11. Freedom Meditech Receives JumpStart Investment
Post Your Comments:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: